BDX logo Becton, Dickinson and Company +
Becton, Dickinson and Company
+

Becton, Dickinson and Company Overview

Company: Becton, Dickinson and Company
CEO: Thomas E. Polen Jr.
Symbol: BDX
Exchange: NYSE
Industry: Medical - Instruments & Supplies
Sector: Healthcare
About

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. Thisludes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care itemsluding needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management,luding pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis,luding fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolioludes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Continue reading...

Becton, Dickinson and Company (BDX)

  • Stock Price
  • Volume
154.88 -35.39 -18.60%
Past 5 Years
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • 10Y
  • ALL

Revenue

Becton, Dickinson and Company annual revenue was $21.84 B in 2025.

Net Income

Becton, Dickinson and Company annual net income was $1.68 B in 2025.

Employees

Becton, Dickinson and Company annual employee count was 72,000 in 2025.

Revenue by Segment

Becton, Dickinson and Company’s revenue by segment: Interventional: $5.22 B, Life Sciences: $5.17 B and Medical: $11.46 B in 2025.

Revenue by Region

Becton, Dickinson and Company’s revenue by region: Asia: $3.09 B, Europe: $4.73 B, Others Country: $1.23 B and UNITED STATES: $12.79 B in 2025.

Executive Salary

Thomas E. Polen Chairman, Chief Executive Officer and President, at ...

Revenue per Employee

Becton, Dickinson and Company revenue per employee was $303.32 K in 2025.

Profit per Employee

Becton, Dickinson and Company profit per employee was $23.31 K in 2025.

Income Statement

Operating Income

Becton, Dickinson and Company annual operating income was $2.58 B in 2025.

Research & Development

Becton, Dickinson and Company annual research & development expense was $1.26 B in 2025.

Tax Rate (%)

Becton, Dickinson and Company annual Tax Rate was 11.00% in 2025.

Assets & Liabilities | Cash Flow

Total Assets

Becton, Dickinson and Company annual total assets was $55.33 B in 2025.

Total Liabilities

Becton, Dickinson and Company annual total liabilities was $29.94 B in 2025.

Capital Expenditure

Becton, Dickinson and Company annual capital expenditures was -$760.00 M in 2025.

Ratios

Return on Equity (ROE)

Becton, Dickinson and Company annual return on equity(ROE) was 0.00% in 2025.

Return on Assets (ROA)

Becton, Dickinson and Company annual return on assets(ROA) was 0.00% in 2025.

Debt to Equity

Becton, Dickinson and Company annual debt to equity was 75.55% in 2025.

Profitability

Gross Profit Margin (%)

Becton, Dickinson and Company annual gross profit margin was 45.44% in 2025.

Operating Income Margin (%)

Becton, Dickinson and Company annual operating income margin was 11.80% in 2025.

Net Income Margin (%)

Becton, Dickinson and Company annual net income margin was 7.68% in 2025.

Earning Per Share

Becton, Dickinson and Company annual earning per share was $5.85 in 2025.

EBITDA

Becton, Dickinson and Company annual EBITDA was $4.96 B in 2025.

Free Cash Flow (FCF)

Becton, Dickinson and Company annual free cash flow(FCF) was $2.67 B in 2025.

Valuation

Enterprise value

Becton, Dickinson and Company annual enterprise value was - in 2025.

Enterprise value to Revenue

Becton, Dickinson and Company annual enterprise value to revenue was 0.00 in 2025.

Enterprise value to EBITDA

Becton, Dickinson and Company annual enterprise value to EBITDA was 0.00 in 2025.

Competitors’ Revenue

Frequently Asked Questions

Who is the CEO of Becton, Dickinson and Company?

Thomas E. Polen Jr. is the CEO of Becton, Dickinson and Company.

What industry and sector is Becton, Dickinson and Company in?

Becton, Dickinson and Company operates in the Medical - Instruments & Supplies industry and the Healthcare sector.

What are Becton, Dickinson and Company's CIK, SIC, and ISIN codes?

  • CIK (Central Index Key): 0000010795
  • SIC (Standard Industrial Classification): 3841
  • ISIN (International Securities Identification Number): US0758871091

Sign up for free to view

How many employees does Becton, Dickinson and Company have?

Becton, Dickinson and Company has 72,000 employees.

What is the revenue of Becton, Dickinson and Company?

In fiscal year 2025, Becton, Dickinson and Company generated a revenue of $21.84 Billion.

What is the net income of Becton, Dickinson and Company?

In fiscal year 2025, Becton, Dickinson and Company reported a net income of $1.68 Billion.

What is Becton, Dickinson and Company's biggest product segment?

Medical is Becton, Dickinson and Company's biggest product segment, representing 52.45% of its total revenue.

When was Becton, Dickinson and Company listed on the stock exchange?

Becton, Dickinson and Company went public on Feb 21, 1973, through its Initial Public Offering (IPO), and it has been 53 years since then.

Sign up for free to view

What is the ticker symbol of Becton, Dickinson and Company, and where is it listed?

Becton, Dickinson and Company's ticker symbol is BDX, and the company is listed on the NYSE stock market exchange.

What is Becton, Dickinson and Company's current stock price?

Becton, Dickinson and Company's current stock price is $154.83 as of Jul 16, 2026.

What is Becton, Dickinson and Company's market capitalization?

As of , Becton, Dickinson and Company's market cap is .

What is Becton, Dickinson and Company's ranking in the world?

Ranked #34among 2,807 companies based on market cap.

Who are the top competitors of Becton, Dickinson and Company?

Competitors of Becton, Dickinson and Company include Intuitive Surgical, and more.

People Also Search For

Submit feedback to Bullfincher